A Look At Adaptive Biotechnologies (ADPT) Valuation After Analyst Upgrades On Strong Q4 Earnings

What triggered the latest focus on Adaptive Biotechnologies? Adaptive Biotechnologies (ADPT) drew fresh investor attention after several analyst firms raised their outlook following what they described as strong Q4 earnings, citing multiple business drivers across its core testing and MRD-focused offerings. See our latest analysis for Adaptive Biotechnologies. At a share price of US$15.39, Adaptive Biotechnologies has recently seen pressure, with a 30 day share price return of 17.04% and a 90 day return of 24.26%. However, the 1 year total shareholder return of 82.78% suggests earlier momentum that now appears to be cooling as the market reassesses growth expectations and risks around its MRD and testing businesses. If Q4 put diagnostics and MRD on your radar, it could be worth seeing what else is moving, starting with our screener of 27 healthcare AI stocks that may interest you. With the stock at US$15.39, recent short term weakness contrasts with strong 1 year gains and analyst targets that sit higher. The key question is whether ADPT is undervalued today or if the market is already pricing in future growth. Most Popular Narrative: 26.2% Undervalued With Adaptive Biotechnologies last closing at US$15.39 against a fair value narrative of US$20.86, the current price sits well below that modeled figure. Marked improvement in profitability, with the MRD segment now EBITDA positive and company wide cash burn improving 36% year over year, signals the business reaching scale and positions Adaptive for operating leverage and expanding net margins as revenue continues to rise. Read the complete narrative. Curious how an unprofitable company still lands on a premium future earnings multiple and double digit growth profile? The narrative leans heavily on MRD traction, margin expansion and a step change in earnings power over time. Using a 7.9% discount rate, the most followed narrative blends assumptions on revenue growth, margin improvement and a high future P/E to arrive at a fair value of US$20.86 per share. That framework leans on MRD scale up, expanding pharma partnerships and eventually healthier profitability to support a higher earnings base and valuation multiple than today. Result: Fair Value of $20.86 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story can break if losses persist at the company level or if key partnerships underperform. This could put pressure on cash needs and future MRD test economics. Find out about the key risks to this Adaptive Biotechnologies narrative. Another View: What Does The Sales Multiple Say? That 26.2% undervalued narrative sits awkwardly next to the current P/S of 8.5x, which looks expensive versus both the US Life Sciences industry at 2.9x and peers at 3.2x, as well as the fair ratio of 3.8x that the market could move toward. Is the story strong enough to justify paying more than double those benchmarks? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ADPT P/S Ratio as at Feb 2026Next Steps Mixed messages in the story so far? Review the full set of data on risks and rewards to clarify your own stance efficiently by starting with 3 key rewards and 2 important warning signs. Looking for more investment ideas? If you stop with just one stock, you could miss opportunities that fit your style far better, so use the screener to widen your field intelligently. Zero in on potential value opportunities by reviewing our 55 high quality undervalued stocks that match stronger fundamentals with more modest pricing. Prioritise resilience by scanning 79 resilient stocks with low risk scores that score well on stability and risk metrics. Get ahead of the crowd by checking our screener containing 23 high quality undiscovered gems before they attract wider attention. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for Free